Background: Peanut allergy is classically managed by food avoidance. Immunotherapy
| INTRODUC TI ON
Standard clinical practice based on the latest management guidelines recommends that patients with peanut allergy avoid all food containing peanut. [1] [2] [3] This is in contrast to milk and egg allergy where baked food products may be recommended where tolerated in select patients as the first stage of milk/egg introduction to promote tolerance and resolution of the allergies.
2,4,5
Immunotherapy (IT) for peanut allergy currently is largely in the domain of research clinical trials. Numerous trials have been shown to successfully increase the amount of peanut that patients tolerate.
6-8
Possible routes of administration include oral, sublingual, or epicutaneous. The oral route, although associated with a greater risk of adverse allergic reactions, has the advantage of allowing larger amounts of peanut to be administered and a greater degree of tolerance.
9,10
Eligibility for enrollment in peanut IT clinical trials is usually, [9] [10] [11] [12] but not always 13, 14 determined after a formal double-blind placebocontrolled food challenge (DBPCFC) to confirm the clinical allergy and the threshold of clinical reactivity. Most regulatory and research studies have focused on clinical reactivity for the lowest 5%-10%
of the population (ED 05 -ED 10 ), calculating it to be between 20 and 70 mg of whole peanut (5-20 mg of peanut protein based on chemical analysis that has previously shown that peanut kernels contain 29% protein). [15] [16] [17] [18] The proportion of patients with higher thresholds of reactivity are less well studied, but it is suggested that 50% of peanut allergic subjects only react to cumulative doses above 100 mg of peanut protein. 19 Patients who react to one peanut are generally excluded from IT clinical trials, as these patients would not be expected to meet the common secondary outcome of an IT-associated increase in the eliciting threshold dose of peanut. These patients are still advised to avoid peanuts as rigorously as those who react to smaller amounts of peanut and carry adrenaline kits.
This international survey aimed to study the full range of thresh- 
| Allergy testing

| Hospital-based peanut OFC
Peanut OFC was performed and directly supervised by the clinical teams at the respective pediatric allergy centers. Open OFC to peanut-containing foods (peanuts, peanut butter, peanut flour, or Bamba snacks) was performed using OFC protocols, increasing the amount of peanut every 15-20 minutes. As such, the amount of peanut quoted in this study refers to weight of whole peanut product, 
| Statistical analysis
Most analyses were performed using the IBM SPSS Statistics 22
program. Continuous variables were quoted as medians and interquartile ranges. Statistical differences between groups were determined by chi-square or Mann-Whitney U tests. Differences were considered statistically significant with a P value <0.05. Multivariate analysis was performed using binary logistic regression. Receiving operating characteristic (ROC) curve analysis was used to display sensitivity and specificity of allergy tests. Dose-distribution modeling was performed using the fitdist function in R v3.4.1. Log-normal, Weibull, and logistic distribution models of the minimum amount of peanut that triggered an allergic reaction on OFC were compared using the Akaike information criteria (AIC). As the log-normal model provided the best fit, this model was used to estimate the amount of peanut (Effective Dose) that resulted in 10% (ED10) or 50% (ED50) of the cohort reacting to peanut on OFC. Difference between the log-normal dose-distribution between Australian and European centers was assessed using the likelihood-ratio test by first fitting the model to all the data and then introducing region as a covariate.
A P value <0.05 was deemed statistically significant. 
| RE SULTS
| Demographics
| Previous history of clinical allergic reactions and sensitization to peanuts
A total of 396 (24%) patients had a history of previous allergic reactions to peanut (Table 1) . Fifty-five (10%) had previously developed respiratory/circulatory signs (anaphylaxis). A total of 879 (54%) patients had never eaten peanuts but had a positive skin prick test (SPT) ≥3 mm, peanut-specific IgE ≥0.35 KU A /L, or both. The remaining 359 (22%) patients had never eaten peanut-containing food and
were not sensitized but because they were unwilling to try peanut for the first time at home, were challenged in hospital.
Of the total cohort, 1193 (73%) patients had evidence of allergic sensitization to peanuts. Sixty percent had a SPT of ≥3 mm, and 20%
had a test result ≥8 mm. Fifty-four percent had a positive specific peanut IgE of ≥0.35 KU A /L and 20% a positive peanut Ara h 2 of ≥0.35 KU A /L. Irish children were significantly more likely to be sensitized to peanut (94%) than Australian (55%) or British children (68%).
The predictive values of allergy tests in relation to the outcome of peanut OFC are shown in Figure 1 and TA B L E 1 Demography and previous investigations Table 2 ). Fifty-three percent of patients with a clear history of previous allergic reactions to peanut passed their OFC, while 30% of patients who had no history of reacting to peanuts failed their OFC.
| Reaction threshold during peanut OFC
A total of 525 (32%) patients developed clinical signs of allergy during the peanut OFC. Demographic factors and allergy test results associated with passing an OFC or failing the challenge after eating >200
and ≤200 mg of peanut are shown in Table 3 . Patients reacting to larger amounts of peanut were significantly older than the other two groups (P < 0.01), and this was independent of other variables in multivariate analysis. Irish children were more likely to react on OFC than children from the UK or Australia. A total of 144 (28%) patients reacted to 25 mg of peanut, while 283 (54%) reacted to 200 mg or more of peanut, 199 (38%) to 1 g or more, and 121 (22%) to 5 g or more.
Threshold of reactivity to peanuts during OFC was determined using dose-distribution modeling (Figure 2 ). Assessment of how well different models fitted the empirical cumulative distribution of the whole data, as determined using Akaike information criteria (AIC),
showed that a log-normal (AIC score 8139) was better than either a Figure 3B ). Clinical history of previous anaphylaxis to peanut was not significantly associated with more severe allergic reactions during OFC, neither was SPT nor peanutspecific IgE result.
| Prevalence of anaphylaxis during peanut OFC
The association between anaphylaxis and the child's age, stage at which they failed their OFC, and the recruiting center was further investigated using multivariate analysis. The age of the child and stage at which they failed their OFC were independently associated with anaphylaxis ( 
| D ISCUSS I ON
This international, multicenter survey provides important results regarding the threshold of clinical reactivity and prevalence of anaphylaxis after a hospital-based peanut OFC. Although, in keeping with previous studies, we showed that the ED10 was only 20 mg of peanut, [15] [16] [17] we found that the ED50 was 300 mg of peanut and 38% of children only reacted after being given more than 1 g of whole peanut.
Ten Although not the primary objective of the study, the data also highlight the fact that clinical history is an imprecise marker of peanut allergy, failing to accurately predict whether a sensitized patient will react to oral ingestion of peanut, the severity of the reaction, and the amount of peanut that will cause a reaction. Diagnosing peanut allergy solely on the basis of history may risk falsely labeling patients as having peanut allergy. Although OFC is considered the gold standard for diagnosing food allergy, Glaumann et al 26 suggest that there may be intra-individual variability in the threshold of reactivity defined by OFC, as they found differences in reactivity when blinded peanut challenges were repeated in the same children.
However, this was a small study of only 27 children, which in contrast to our survey, assessed outcome of the OFC on not only clinical signs of allergy but also subjective symptoms of "mouth itch," "stomach ache," "tiredness." Recent publications from our centers have demonstrated the clinical utility of these measures to maintain a level of tolerance, with the possibility of improving the degree of nonresponsiveness in some patients in a manner similar to a desensitization regime. 30, 31 In summary, this survey highlights both the under-appreciated spectrum of reactivity to peanuts and that avoiding peanuts through childhood may well be a factor leading to increased clinical reactivity and severity. Further work is required to explore the impact and practicality of IT for these patients.
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